GeneDx Holdings (WGS) Cash Flow: Operating & Free Cash Flow

GeneDx Holdings Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for GeneDx Holdings Corp. (WGS) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Operating Activities
Net Income	-21.02	-52.29	-175.77	-548.98	-245.39	-241.34
Depreciation & Amortization	25.22	21.95	33.73	59.31	21.81	11.73
Deferred Income Tax	0.00	-0.34	-0.93	-49.12	0.00	0.00
Stock Based Compensation	32.16	9.14	-0.33	41.98	219.42	120.23
Change in Working Capital	-15.60	-24.75	-38.24	33.88	8.08	13.85
Change in Accounts Receivable	-36.23	-5.42	10.53	5.53	5.54	-10.61
Change in Inventory	-3.44	-2.59	0.98	2.35	-10.62	-8.98
Change in Accounts Payable	12.10	-20.46	-49.17	34.46	0.00	0.00
Change in Other Working Capital	11.97	17.26	-0.58	-8.46	13.17	33.44
Other Operating Activities	12.51	17.26	0.45	94.66	-194.35	2.40
Net Cash from Operating Activities	33.28	-28.50	-180.15	-319.16	-190.43	-93.13
Investing Activities
Capital Expenditures	-19.02	-5.49	-5.25	-7.16	-20.79	-31.97
Acquisitions	-32.86	0.00	-67.82	-127.00	0.00	0.00
Purchases of Investments	-9.64	-66.30	-47.67	0.00	0.00	0.00
Sales/Maturities of Investments	46.03	41.66	17.77	-7.17	0.00	0.00
Other Investing Activities	0.00	0.00	0.00	0.00	-11.39	-7.88
Net Cash from Investing Activities	-61.52	-30.13	-43.73	-141.33	-20.79	-31.97
Financing Activities
Debt Repayment	-1.21	-3.23	-2.00	-3.29	-13.47	11.73
Common Stock Issued	51.69	46.50	143.29	200.61	442.68	0.00
Other Financing Activities	-2.45	0.89	-3.60	-3.29	64.51	117.32
Net Cash from Financing Activities	48.03	44.16	186.24	197.32	493.73	129.06
Summary
Effect of Forex Changes on Cash	0.00	0.00	-0.09	0.00	0.00	0.00
Net Change in Cash	19.79	-14.47	-37.64	-263.17	282.51	3.95
Cash at Beginning of Period	86.20	100.67	138.30	401.47	118.96	115.01
Cash at End of Period	105.99	86.20	100.67	138.30	401.47	118.96
Free Cash Flow	14.26	-33.99	-185.40	-326.31	-211.22	-125.10
Supplemental Disclosures
Interest Paid	6.41	6.68	3.04	1.93	2.75	-
Income Taxes Paid	1.28	1.17	1.47	1.24	0.35	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About GeneDx Holdings Cash Flow

What is GeneDx Holdings's free cash flow?

GeneDx Holdings generated free cash flow of $14.26M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of $33.28M minus $19.02M of capital expenditures. Free cash flow equaled 3.3% of revenue.

How much does GeneDx Holdings spend on capital expenditures?

GeneDx Holdings spent $19.02M on capital expenditures in fiscal 2025, compared with $5.49M a year earlier. That equals 57.1% of operating cash flow.

Does GeneDx Holdings pay dividends or buy back shares?

GeneDx Holdings's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition